

Annex 10A Methodologies Used for Impact of EPI Vaccines and New Gavi-Supported Vaccines

Supplemental material for: Feikin, DR, B Flannery, MJ Hamel, M Stack, and PM Hansen. 2016. Vaccines for Children in Low- and Middle-Income Countries. In: *Reproductive, Maternal, Newborn, and Child Health*, edited by RE Black, R Laxminarayan, M Temmerman, and N Walker. Volume 2 of *Disease Control Priorities, third edition*. Washington, DC: World Bank.

Measles

Using a dynamic population-based Markov model developed by Pennsylvania State University and WHO (Chen, Fricks et al. 2012; Simons, Ferrari et al. 2012).

Hepatitis B

Because disease develops over many years, impact of vaccination programs are modeled over the lifetime of birth cohorts. Numbers of expected hepatitis B deaths averted were estimated using a static cohort model based on the natural history of hepatitis B disease developed by the US Centers for Disease Control and Prevention (Goldstein, Zhou, et al 2005). Underlying rates of hepatitis B infection in the model were based on pre-vaccination seroprevalence studies (Goldstein, Zhou, et al 2005).

Hib

Estimates of deaths averted by Hib vaccination were calculated using the Lives Saved Tool (LiST) developed by Johns Hopkins University (Winfrey, McKinnon et al. 2011). Consistent with the approach used to estimate global Hib pneumonia disease burden (Watt, Wolfson et al. 2009; Theodoratou, Johnson et al. 2010) estimates of the proportion of under-five pneumonia deaths due to Hib pneumonia were derived by applying the proportionate reduction in radiologically confirmed pneumonia cases observed in Hib vaccine probe studies to WHO/CHERG country-specific estimates of the proportion of under-five deaths due to pneumonia in 2000 (Bryce, Boschi-Pinto et al. 2005; Liu, Johnson et al. 2012).

Pneumococcus

Estimates of deaths averted by pneumococcal vaccination were calculated using the LiST tool developed by Johns Hopkins University (Winfrey, McKinnon et al. 2011). The same approach was used to estimate pneumonia deaths due to pneumococcus as described above for pneumonia deaths due to Hib.

Rotavirus

Estimates of deaths averted by rotavirus vaccination were calculated using the LiST tool developed by Johns Hopkins University (Winfrey, McKinnon et al. 2011). To estimate the number of deaths caused by rotavirus, WHO country-specific estimates of under-five deaths due to diarrhea were multiplied by an estimated 39 percent of cases of severe clinical gastroenteritis caused by rotavirus based on 41 hospital-based surveillance studies (Parashar, Gibson et al. 2006; Fischer Walker, Munos et al. 2013). In 2008, it was estimated that 453,000 deaths occurred due to rotavirus worldwide (Tate, Burton et al. 2012), although a more recent estimate using a different methodology and diarrhea mortality envelope estimated 193,000 rotavirus deaths in 2010 (Walker, Rudan et al. 2013).

Rubella

Estimates of CRS disease burden are based on surveillance data, serologic surveys of childbearing-aged women and mathematical modeling. Review of worldwide data on CRS in developing countries suggested incidence of 0.6 to 2.2 cases per 1000 live births, similar to rates seen in developing countries before universal vaccination (Reef and Plotkin, 2013). Estimates of the number of CRS cases averted by vaccination were calculated using a dynamic transmission model developed in 2011 by the UK Health

Protection Agency and extended from previous modeling work (Cutts and Vynnycky 1999; Vynnycky, Gay et al. 2003). This model projects the number of women of childbearing age susceptible to rubella infection by country and year through the lifetime of each vaccinated cohort. Estimates of CRS deaths averted were calculated assuming a proportional case fatality ratio of 30 percent in all countries (De Owens and De Espino 1989; Lawn, Reef et al. 2000; Al-Awaidy, Griffiths et al. 2006; Lanzieri, Pinto et al. 2007).

Meningococcus

To calculate these figures, estimates of 1.04 deaths averted per 1,000 persons vaccinated through mass vaccination campaigns and 0.08 deaths averted per 1,000 infants vaccinated through routine vaccination were applied to projected numbers of persons vaccinated. These rates were based on an analysis conducted by PATH using a generalized static cohort model to estimate the impact of a WHO and UNICEF investment case (LaForce and Okwo-Bele 2011). Underlying *Neisseria meningitidis* serogroup A incidence used in the model was based on a prospective hospital-based surveillance study of meningitis in Niger conducted during 1981–1996 (Campagne, Schuchat et al. 1999). The model assumed a ten-year inter-epidemic interval and a 12 percent case fatality ratio.

Yellow Fever

An estimate of 0.2 epidemic yellow fever deaths averted per 1,000 persons vaccinated, derived from a 1993 study that modeled the impact of routine infant yellow fever vaccination in Nigeria (Monath and Nasidi 1993), was applied to projected numbers of persons vaccinated to estimate deaths averted during 2000–2020. The reference study utilized a static cohort model based on the assumption that, on average, epidemics occur at 17-year intervals, 4 million persons are affected in each epidemic, there is an epidemic infection rate of 20%, and 20 percent case fatality ratio.

Japanese Encephalitis

Estimates of Japanese encephalitis deaths averted were calculated using a static cohort model developed by PATH, modified from models developed for Cambodia and India (Suraratdecha, Jacobson et al. 2006; Touch, Suraratdecha et al. 2010). Underlying incidence rates used in the model estimates were based on a recent review of population-based surveillance studies (Campbell, Hills et al. 2011). Country-specific proportional case fatality ratios were based on a review of published and unpublished surveillance data and ranged from 10 to 25 percent (Sohn 2000; Solomon, Dung et al. 2000; Kari, Liu et al. 2006).

For the new vaccines, we used a methodology recently adopted through an expert process with leading modeling groups co-convened by Gavi, The Vaccine Alliance and Bill and Melinda Gates Foundation to estimate impact of vaccinations administered in the 73 Gavi-supported countries (table 10A.3). The methods and results from the first round of modeling were published (Lee, Franzel et al. 2013), covering vaccinations forecasted to be administered in Gavi-supported countries from 2011–20. Numbers of deaths averted were calculated as the difference in deaths expected to occur over the lifetime of vaccinated cohorts compared to the number of deaths expected to occur in those cohorts without vaccination. We provide an update of this analysis covering vaccinations administered from 2000–2012 and updated forecasts of vaccinations expected to occur between 2013 and 2020 based on the Gavi, The Vaccine Alliance Strategic Demand Forecast version. Similar evidence on the projected impact of new vaccines in non-Gavi eligible countries would also be valuable to decision-makers in those countries and globally, but at present no systematic and standardized demand forecast exists that projects vaccination uptake and use in such countries.

Table 10A.1 Models Used To Estimate Averted Cases and Deaths from Administration of Original EPI Vaccines and New and Underutilized Vaccines Supported by Gavi

Vaccines	Vaccination strategies	Model source	Model structure	Underlying disease burden
Measles	routine and campaign	Chen, Fricks et al. 2012; Simons, Ferrari et al. 2012 (Pennsylvania State University and WHO)	Dynamic population-based Markov model informed by surveillance data	Case-fatality ratios for children <5 years and 5-9 years applied to age distribution derived from case-based surveillance data, using first dose coverage and region as covariates
Hepatitis B	Routine	Goldstein et al, 2005 (U.S. Centers for Disease Control and Prevention)	Static natural history population-based cohort	Pre-vaccination hepatitis B surface antigen (HBsAg) serosurvey data
Haemophilus influenzae type b (Hib)	Routine	Lives Saved Tool model (Johns Hopkins University)	Static cohort	Pneumonia deaths <5 years (WHO) x Hib vaccine preventable burden of radiographic pneumonia
Pneumococcal	Routine	Lives Saved Tool model (Johns Hopkins University)	Static cohort	Pneumonia deaths <5 years (WHO) x pneumococcal conjugate vaccine preventable burden of radiographic pneumonia
Rotavirus	Routine	Lives Saved Tool model (Johns Hopkins University)	Static cohort	Diarrhea deaths <5 years (WHO) x proportion of severe gastroenteritis due to rotavirus infection
Rubella	campaign & routine	UK Health Protection Agency Centre for Infections, CDC, WHO	Dynamic cohort	Pre-vaccination rubella serosurveys to determine age-specific incidence
Meningococcal serogroup A	campaign & routine	Long Range Cost and Impact model (Gavi)	Deaths averted per 1,000 vaccinated	Pre-vaccination prospective hospital surveillance study in Niger, 1981-1996
Yellow fever	Routine	Long Range Cost and Impact model (Gavi)	Deaths averted per 1,000 vaccinated	Model based on disease burden studies in Nigeria
Japanese encephalitis	campaign & routine	PATH	Static cohort	Population based surveillance studies

Table 1 HepB = Hepatitis B; Hib = Haemophilus influenza type b; JE = Japanese encephalitis; PCV = pneumococcal conjugate vaccine; MenA = Meningococcus serotype A; MSD = measles second dose; Rota = rotavirus; YF = Yellow Fever.

Table 10A.2 Characteristics of Common Childhood Vaccines

Vaccine (common abbreviations)	Type of vaccine	Diseases prevented	No. countries with routine vaccination, 2012	No. (%) of 73 GAVI countries with routine vaccination, 2012	Schedule	Vaccine efficacy	Duration of immunity	Estimated deaths in children < 5 years, rounded to thousands (2012 unless indicated)	Source for deaths
<i>Recommended vaccines for national immunization programs in all low- and middle-income countries</i>									
Bacille Calmette-Guérin (BCG)	Live-attenuated <i>Mycobacterium bovis</i>	Disseminated disease and meningitis caused by <i>M. tuberculosis</i>	159	69 (95%)	1 dose at birth	75-86%	Unknown	55,000	WHO 2014
Diphtheria, Tetanus, Pertussis (DTP, DTwP or DTaP)	Diphtheria toxoid, tetanus toxoid, killed whole cell (wP) or acellular (aP) <i>Bordatella pertussis</i>	Diphtheria, tetanus, pertussis	194	73 (100%)	3 doses age ≤6 months + boosters	70-90% pertussis; >95% tetanus; >87% diphtheria	5-10 years; more waning with acellular vaccine	Diphtheria 1,000; pertussis 63,000, tetanus 56,000	WHO 2014
Oral Polio (OPV)	Live-attenuated Sabin poliovirus type 1, 2, 3 (monovalent, bivalent [1,3] or trivalent)	Poliomyelitis	159	73 (100%)	At birth + 3 doses age ≤6 months + boosters	~90%	Lifelong	<1	Global Polio Eradication Initiative
Inactivated Polio (IPV)	Inactivated wild poliovirus type 1, 2, 3 (trivalent)	Poliomyelitis	66	1 (1%)	3 doses age ≤6 months + boosters	80-90%		<1	Global Polio Eradication Initiative

Measles, Measles-containing vaccine (M, MR, MMR)	Live-attenuated measles virus	Measles	194	73 (100%)	9-15 months, 1st dose; 15+ months 2nd dose	85-95%	Lifelong in most; some waning after one dose	101,000	WHO, 2014
Haemophilus influenzae type b conjugate (Hib)	Hib polysaccharide-protein conjugate	Hib diseases (meningitis, pneumonia)	180	68 (93%)	3 doses age ≤6 months	>85% invasive disease		203,000 (2008); 197,000 (2010)	Watt, 2009;WHO, 2013c
Hepatitis B (HB)	Recombinant hepatitis B surface antigen		181	71 (97%)	At birth + 2 or 3 doses age ≤6 months	75-95%	>15 years	5,000	WHO, 2014
Pneumococcal conjugate (PCV)	Pneumococcal polysaccharide-protein conjugate (10- or 13-valent)	Pneumococcal diseases (meningitis, pneumonia)	88	23 (32%)	3 doses age ≤6 months, or 2 or 3 doses ≤6 months + booster 9-15 months	>70% vaccine-serotype invasive disease	At least 5 years	541,000 (2008); 411,000 (2010)	O'Brien 2009;WHO, 2013b
Rotavirus (RV)	Live-attenuated (RV1) reassortment or bovine-human (RV5)	Rotavirus gastroenteritis	41	11 (15%)	2 or 3 doses age ≤6 months (different vaccines)	50-77% severe gastroenteritis	Waning in 2nd year of life	453,000 (2008); 193,000 (2010)*	Tate 2012; Walker 2013
Rubella, Rubella-containing vaccine (R, RCV)	Live-attenuated rubella virus	Rubella, congenital rubella syndrome	132	20 (27%)	1 dose age ≥9 months	95%	Lifelong in most; rare waning after one dose	30,000 (no year)	Cutts 1999; Lee 2013

Recommendations for certain regions or high-risk populations

Meningococcal serogroup A conjugate (MenA)	Polysaccharide-protein conjugate	Meningococcal meningitis and disease due to serogroup A	12 of 25 high-risk countries	12 of 25 high-risk countries	Under evaluation	> 95%	unknown	10,000/year (all ages, 1993 to 2012)	WHO 2013a
Yellow Fever (YF)	Live-attenuated yellow fever virus	Yellow fever	37 of 48 high-risk countries	24 (33%)	1 dose age ≥ 9 months	90-98%	Lifelong	29,000-60,000	WHO 2013c
Japanese Encephalitis (JE)	Live-attenuated Japanese encephalitis virus	Encephalitis	10	5 (7%)		90%	unknown	10,000/year (ages 0-14)	Campbell, Hills et al. 2011
Oral Cholera (OCV)	Killed, whole cell <i>Vibrio cholerae</i>	Cholera	N/A	N/A	2 doses age ≥ 1 year	67-80%	Effectiveness shown for 6 months to 2 years	45,000	Ali et al. 2012; Sack 2014

*Note that the 2008 and 2010 estimates used different methodologies and overall diarrhea mortality envelopes.

Table 10A.3 New and Underused Vaccines Introduced into Routine Immunization Programs in 73 Gavi Countries through the End of 2014

Country	Region	HepB	Hib	PCV	JE	YF	MSD	Rubella	Rotavirus
Afghanistan	EMRO	X	X	X			X		
Angola	AFRO	X	X	X		X			X
Armenia	EURO	X	X	X			X		X
Azerbaijan	EURO	X	X	X			X		
Bangladesh	SEARO	X	X	X			X	X	
Benin	AFRO	X	X	X		X			
Bhutan	SEARO	X	X				X	X	
Bolivia	AMRO	X	X	X		X		X	X
Burkina Faso	AFRO	X	X	X		X	X		X
Burundi	AFRO	X	X	X			X		X
Cambodia	WPRO	X	X	X	X		X	X	
Cameroon	AFRO	X	X	X		X			X
Central African Republic	AFRO	X	X	X		X			
Chad	AFRO	X	X			X			
Comoros	AFRO	X	X						
Congo, Democratic Republic	AFRO	X	X	X		X			
Congo, Republic	AFRO	X	X	X		X			X
Côte d'Ivoire	AFRO	X	X	X		X			
Cuba	AMRO	X	X				X	X	
Djibouti	EMRO	X	X	X			X		X
Eritrea	AFRO	X	X				X		X
Ethiopia	AFRO	X	X	X					X
Gambia	AFRO	X	X	X		X	X		X
Georgia	EURO	X	X	X			X	X	X
Ghana	AFRO	X	X	X		X	X	X	X
Guinea	AFRO	X	X			X			
Guinea-Bissau	AFRO	X	X			X			
Guyana	AMRO	X	X	X		X	X	X	X
Haiti	AMRO	X	X					X	X
Honduras	AMRO	X	X	X				X	X
India	SEARO	X	X		X		X		
Indonesia	SEARO	X	X				X		
Kenya	AFRO	X	X	X		X	X		X
Kiribati	WPRO	X	X	X			X	X	
Korea, Dem. People's Republic	SEARO	X	X				X		
Kyrgyzstan	EURO	X	X				X	X	
Lao People's Democratic Republic	WPRO	X	X	X	X		X	X	
Lesotho	AFRO	X	X				X		
Liberia	AFRO	X	X	X		X			

Madagascar	AFRO	X	X	X					X
Malawi	AFRO	X	X	X					X
Mali	AFRO	X	X	X		X			X
Mauritania	AFRO	X	X	X					X
Moldova	EURO	X	X	X			X	X	X
Mongolia	WPRO	X	X				X	X	
Mozambique	AFRO	X	X	X					
Myanmar	SEARO	X	X				X		
Nepal	SEARO	X	X	X	X			X	
Nicaragua	AMRO	X	X	X			X	X	X
Niger	AFRO	X	X	X		X			X
Nigeria	AFRO	X	X	X		X			
Pakistan	EMRO	X	X	X			X		
Papua New Guinea	WPRO	X	X	X			X		
Rwanda	AFRO	X	X	X				X	X
Sao Tome and Principe	AFRO	X	X	X		X	X		
Senegal	AFRO	X	X	X		X	X	X	X
Sierra Leone	AFRO	X	X	X		X			X
Solomon Islands	WPRO	X	X	X			X	X	
Somalia	EMRO	X	X						
Sri Lanka	SEARO	X	X		X		X	X	
Sudan	EMRO	X	X	X			X		X
South Sudan	EMRO	X	X						
Tajikistan	EURO	X	X				X	X	X
Tanzania	AFRO	X	X	X				X	X
Timor-Leste	SEARO	X	X						
Togo	AFRO	X	X	X		X			X
Uganda	AFRO	X	X	X					
Ukraine	EURO	X	X				X	X	
Uzbekistan	EURO	X	X				X	X	X
Vietnam	WPRO	X	X		X		X		
Yemen	EMRO	X	X	X			X	X	X
Zambia	AFRO	X	X	X			X		X
Zimbabwe	AFRO	X	X	X					X
Total Countries		73	73	50	6	24	40	26	35

Note: The estimates were produced through an expert modeling process convened by Gavi and the Bill and Melinda Gates Foundation, in partnership with the World Health Organization, which updated the estimates described in Lee and others (2013). The source for forecasted dates and coverage levels for future vaccine introductions is Gavi's Strategic Demand Forecast, version 9. The methods for estimating future DALYs averted are described in Ozawa and others forthcoming.

References

- Al-Awaidy, S., U. K. Griffiths, et al. 2006. "Costs of Congenital Rubella Syndrome (CRS) in Oman: Evidence Based on Long-Term Follow-Up of 43 Children." *Vaccine* 24 (40): 6437-45.
- Ali, M., et al. 2012. "The Global Burden of Cholera." *Bulletin of the World Health Organization* 90: 209–218A.
- Bryce, J., C. Boschi-Pinto, et al. 2005. "WHO Estimates of the Causes of Death in Children." *The Lancet* 365 (9465): 1147-52.
- Campagne, G., A. Schuchat, et al. 1999. "Epidemiology of Bacterial Meningitis in Niamey, Niger, 1981-96." *Bulletin of the World Health Organization* 77 (6): 499-508.
- Campbell, G. L., S. L. Hills, et al. 2011. "Estimated Global Incidence of Japanese Encephalitis: A Systematic Review." *Bulletin of the World Health Organization* 89 (10): 766-774.
- Chen, S., J. Fricks, et al. 2012. "Tracking Measles Infection through Non-Linear State Space Models." *Journal of the Royal Statistical Society: Series C (Applied Statistics)* 61 (1): 117-34.
- Cutts, F. T., and E. Vynnycky 1999. "Modelling the Incidence of Congenital Rubella Syndrome in Developing Countries." *International Journal of Epidemiology* 28 (6): 1176-84.
- De Owens, C. S. and R. T. De Espino. 1989. "Rubella in Panama: still a problem." *The Pediatric Infectious Disease Journal* no. 8(2): 110-115.
- Fischer Walker, C. L., M. K. Munos, et al. 2013. "Quantifying the Indirect Effects of Key Child Survival Interventions for Pneumonia, Diarrhoea, and Measles." *Epidemiology & Infection* 141 (1): 115-31.
- Global Polio Eradication Initiative. Data and Monitoring. <http://www.polioeradication.org>.
- Goldstein, S. T., F. Zhou, et al. 2005. "A Mathematical Model To Estimate Global Hepatitis B Disease Burden and Vaccination Impact." *International Journal of Epidemiology* 34 (6): 1329-39.
- Kari, K., W. Liu, et al. 2006. "A Hospital-Based Surveillance for Japanese Encephalitis in Bali, Indonesia." *BMC Medicine* 4 (1): 8.
- Laforce, F. M., and J. M. Okwo-Bele 2011. "Eliminating Epidemic Group A Meningococcal Meningitis in Africa Through a New Vaccine." *Health Affairs* 30 (6): 1049-57.
- Lanzieri, T. M., D. Pinto, et al. 2007. "Impact of Rubella Vaccination Strategy on the Occurrence of Congenital Rubella Syndrome." *Jornal De Pediatria* 83 (5): 415-21.
- Lawn, J. E., S. Reef, et al. 2000. "Unseen Blindness, Unheard Deafness, and Unrecorded Death and Disability: Congenital Rubella in Kumasi, Ghana." *American Journal of Public Health* 90 (10): 1555.
- Lee, L. A., L. Franzel, et al. 2013. "The Estimated Mortality Impact of Vaccinations Forecast To Be Administered during 2011-2020 in 73 Countries Supported By the GAVI Alliance." *Vaccine* 31 (Suppl 2): B61-72.
- Liu, L., H. L. Johnson, et al. 2012. "Global, Regional, and National Causes of Child Mortality: An Updated Systematic Analysis for 2010 with Time Trends since 2000." *The Lancet* 379 (9832): 2151-61.
- Monath, T. P., and A. Nasidi. 1993. "Should Yellow Fever Vaccine Be Included in the Expanded Program of Immunization in Africa? A Cost-Effectiveness Analysis for Nigeria." *American Journal of Tropical Medicine and Hygiene* 48 (2): 274.
- O'Brien, K. L., L. J. Wolfson, et al. 2009. "Burden of Disease Caused by Streptococcus Pneumoniae in Children Younger Than 5 Years: Global Estimates." *The Lancet* 374 (9693): 893-902.
- Parashar, U. D., C. J. Gibson, et al. 2006. "Rotavirus and Severe Childhood Diarrhea." *Emerging Infectious Diseases* 12 (2): 304-06.

- Reef, S. E., and S. A. Plotkin. 2013. "Rubella Vaccine." In *Vaccines, 6th Edition*, edited by S. A. Plotkin, W. A. Orenstein, and P. A. Offit, 688-717. Philadelphia: Saunders.
- Sack, D. 2014. "Cholera Burden Of Disease Estimates."
<http://www.jhsph.edu/Dept/jh/globalhealthresearch/cholera/index.html>.
- Simons, E., M. Ferrari, et al. 2012. "Assessment of the 2010 Global Measles Mortality Reduction Goal: Results from a Model of Surveillance Data." *The Lancet* 379 (9832): 2173-78.
- Sohn, Y. M. 2000. "Japanese Encephalitis Immunization in South Korea: Past, Present, and Future." *Emerging Infectious Diseases* 6 (1): 17.
- Solomon, T., N. M. Dung, et al. 2000. "Japanese Encephalitis." *Journal Of Neurology, Neurosurgery & Psychiatry* 68 (4): 405-15.
- Suraratdecha, C., J. Jacobson, et al. 2006. "A Cost-Effectiveness Analysis of Strategies for Controlling Japanese Encephalitis in Andhra Pradesh, India." *Journal of Pharmaceutical Finance Economics & Policy* 15 (1): 21.
- Tate, J. E., A. H. Burton, et al. 2012. "2008 Estimate of Worldwide Rotavirus-Associated Mortality in Children Younger Than 5 Years before the Introduction of Universal Rotavirus Vaccination Programmes: A Systematic Review and Meta-Analysis." *The Lancet Infectious Diseases* 12 (2): 136-41.
- Theodoratou, E., S. Johnson, et al. 2010. "The Effect of Haemophilus Influenzae Type B and Pneumococcal Conjugate Vaccines on Childhood Pneumonia Incidence, Severe Morbidity and Mortality." *International Journal of Epidemiology* 39 (Suppl 1): I172-85.
- Touch, S., C. Suraratdecha, et al. 2010. "A Cost-Effectiveness Analysis of Japanese Encephalitis Vaccine in Cambodia." *Vaccine* 28 (29): 4593-99.
- Vynnycky, E., N. Gay, et al. 2003. "The Predicted Impact of Private Sector MMR Vaccination on the Burden of Congenital Rubella Syndrome." *Vaccine* 21 (21): 2708-19.
- Walker, C. L., I. Rudan, L. Liu, H. Nair, E. Theodoratou, and others. 2013. "Global Burden of Childhood Pneumonia and Diarrhoea." *The Lancet* 381 (9875): 1405-16.
- Watt, J. P., L. J. Wolfson, et al. 2009. "Burden of Disease Caused by Haemophilus Influenzae Type B in Children Younger than 5 Years: Global Estimates." *The Lancet* 374 (9693): 903-11.
- WHO (World Health Organization). 2013a. "Meningococcal Disease in Countries of the African Meningitis Belt, 2012: Emerging Needs and Future Perspectives." *Weekly Epidemiological Record* 88 (12): 129-36.
- WHO. 2013b. "Immunization Surveillance, Assessment and Monitoring."
http://www.who.int/Immunization_Monitoring/Burden/Pneumo_Hib_Estimates/En/Index.Html.
- WHO. 2013c. "Meeting of the Strategic Advisory Group of Experts on Immunization, April 2013: Conclusions and Recommendations." *Weekly Epidemiological Record* 88 (20): 201-16.
- WHO. 2014. "Global Health Estimates."
http://www.who.int/healthinfo/Global_Burden_Disease/gbd/en/index.html.